EXPLAINER-How worried should we be about blood clots linked to Astra, J&J vaccines? Reuters 1 hr ago
(Adds details following EMA warning label for J&J vaccine)
By John Miller and Ludwig Burger
ZURICH, April 21 (Reuters) - European regulators said the benefits of using Johnson & Johnson s and AstraZeneca s COVID-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting.
J&J said on April 20 it would resume deliveries of its vaccine in Europe, following the regulator s guidance. U.S. officials are continuing their review of what are now eight reported instances of rare clotting combined with low blood platelets in the United States.
J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Covid explainer: Do we need to worry about blood clots linked to vaccines?
Reuters/Zurich Reuters file
Regulators confirm that the blood clots are extremely rare and the benefits of AstraZeneca and J&J vaccines outweigh risks
European regulators said the benefits of using Johnson & Johnson s and AstraZeneca s Covid-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting.
J&J said on April 20 it would resume deliveries of its vaccine in Europe, following the regulator s guidance. US officials are continuing their review of what are now eight reported instances of rare clotting combined with low blood platelets in the United States.
By John Miller and Ludwig Burger ZURICH (Reuters) - European regulators said the benefits of using Johnson & Johnson s and AstraZeneca s COVID-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting. J&J said on April 20 it would resume deliveries of its vaccine in Europe, following the regulator s guidance. U.S. officials are continuing their review of what are now eight reported instances of rare clotting combined with low blood platelets in the United States. Britain s health regulator has recommended people under the age of 30 get an alternative COVID-19 vaccine, if possible, rather than the AstraZeneca shot, while some other European countries are only administering the shot to older people. Amid concerns that rare side effect reports could undermine confidence, vaccine and immunology experts said clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing COVID-1